Targeted Therapies and Developing Precision Medicine in Gastric Cancer

Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, va...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-06, Vol.15 (12), p.3248
Main Authors: Pihlak, Rille, Fong, Caroline, Starling, Naureen
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Cancer therapies
Chemotherapy
Drug therapy
ErbB-2 protein
FDA approval
Gastric cancer
Immunotherapy
Ipilimumab
Medical research
Medicine, Experimental
Patients
Population
Precision medicine
Response rates
Review
Stomach cancer
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073
cites cdi_FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073
container_end_page
container_issue 12
container_start_page 3248
container_title Cancers
container_volume 15
creator Pihlak, Rille
Fong, Caroline
Starling, Naureen
description Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, various new targets and novel treatments have recently been investigated and have shown promise in improving survival outcomes. In this review, we will summarise previous and currently ongoing studies on predictive biomarkers, possible new targeted treatments, potential reasons for conflicting trial results and hope for the future of precision medicine in gastric cancer.
doi_str_mv 10.3390/cancers15123248
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10296575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A754975974</galeid><sourcerecordid>A754975974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073</originalsourceid><addsrcrecordid>eNptkUtPAyEUhYnRWKNduzOTuHFT5c2wMqY-E40u6pogc6fFTKHC1MR_L76rERYQ-M7hXg5CuwQfMqbxkbPBQcpEEMoor9fQFsWKjqTUfH1lP0DDnB9xGYwRJdUmGjDFFK5FvYXOJzZNoYemmswg2YWHXNnQVKfwDF1c-DCt7hI4n30M1Q003vkAlQ_Vhc198q4avxexgzZa22UYfq7b6P78bDK-HF3fXlyNT65Hjte6H8nGUdvWjmMppJaNaGssMZGcARVSAlGU2abljlheA7MMHihvNXAHoBlWbBsdf_gulg9zaByEPtnOLJKf2_RiovXm903wMzONz4ZgqqVQojgcfDqk-LSE3Ju5zw66zgaIy2xozbAspJYF3f-DPsZlCqW_QlGtSu1a_1BT24HxoY3lYfdmak6U4FoJrXihDv-hymxg7l0M0Ppy_ktw9CFwKeacoP1ukmDzFr_5E39R7K3-zTf_FTZ7BXk2qng</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829780699</pqid></control><display><type>article</type><title>Targeted Therapies and Developing Precision Medicine in Gastric Cancer</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central Free</source><creator>Pihlak, Rille ; Fong, Caroline ; Starling, Naureen</creator><creatorcontrib>Pihlak, Rille ; Fong, Caroline ; Starling, Naureen</creatorcontrib><description>Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, various new targets and novel treatments have recently been investigated and have shown promise in improving survival outcomes. In this review, we will summarise previous and currently ongoing studies on predictive biomarkers, possible new targeted treatments, potential reasons for conflicting trial results and hope for the future of precision medicine in gastric cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15123248</identifier><identifier>PMID: 37370858</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Cancer ; Cancer therapies ; Chemotherapy ; Drug therapy ; ErbB-2 protein ; FDA approval ; Gastric cancer ; Immunotherapy ; Ipilimumab ; Medical research ; Medicine, Experimental ; Patients ; Population ; Precision medicine ; Response rates ; Review ; Stomach cancer ; Survival ; Tumors</subject><ispartof>Cancers, 2023-06, Vol.15 (12), p.3248</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073</citedby><cites>FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073</cites><orcidid>0000-0002-1496-6792 ; 0000-0002-6055-334X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2829780699/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2829780699?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37370858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pihlak, Rille</creatorcontrib><creatorcontrib>Fong, Caroline</creatorcontrib><creatorcontrib>Starling, Naureen</creatorcontrib><title>Targeted Therapies and Developing Precision Medicine in Gastric Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, various new targets and novel treatments have recently been investigated and have shown promise in improving survival outcomes. In this review, we will summarise previous and currently ongoing studies on predictive biomarkers, possible new targeted treatments, potential reasons for conflicting trial results and hope for the future of precision medicine in gastric cancer.</description><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Drug therapy</subject><subject>ErbB-2 protein</subject><subject>FDA approval</subject><subject>Gastric cancer</subject><subject>Immunotherapy</subject><subject>Ipilimumab</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Patients</subject><subject>Population</subject><subject>Precision medicine</subject><subject>Response rates</subject><subject>Review</subject><subject>Stomach cancer</subject><subject>Survival</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkUtPAyEUhYnRWKNduzOTuHFT5c2wMqY-E40u6pogc6fFTKHC1MR_L76rERYQ-M7hXg5CuwQfMqbxkbPBQcpEEMoor9fQFsWKjqTUfH1lP0DDnB9xGYwRJdUmGjDFFK5FvYXOJzZNoYemmswg2YWHXNnQVKfwDF1c-DCt7hI4n30M1Q003vkAlQ_Vhc198q4avxexgzZa22UYfq7b6P78bDK-HF3fXlyNT65Hjte6H8nGUdvWjmMppJaNaGssMZGcARVSAlGU2abljlheA7MMHihvNXAHoBlWbBsdf_gulg9zaByEPtnOLJKf2_RiovXm903wMzONz4ZgqqVQojgcfDqk-LSE3Ju5zw66zgaIy2xozbAspJYF3f-DPsZlCqW_QlGtSu1a_1BT24HxoY3lYfdmak6U4FoJrXihDv-hymxg7l0M0Ppy_ktw9CFwKeacoP1ukmDzFr_5E39R7K3-zTf_FTZ7BXk2qng</recordid><startdate>20230619</startdate><enddate>20230619</enddate><creator>Pihlak, Rille</creator><creator>Fong, Caroline</creator><creator>Starling, Naureen</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1496-6792</orcidid><orcidid>https://orcid.org/0000-0002-6055-334X</orcidid></search><sort><creationdate>20230619</creationdate><title>Targeted Therapies and Developing Precision Medicine in Gastric Cancer</title><author>Pihlak, Rille ; Fong, Caroline ; Starling, Naureen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Drug therapy</topic><topic>ErbB-2 protein</topic><topic>FDA approval</topic><topic>Gastric cancer</topic><topic>Immunotherapy</topic><topic>Ipilimumab</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Patients</topic><topic>Population</topic><topic>Precision medicine</topic><topic>Response rates</topic><topic>Review</topic><topic>Stomach cancer</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pihlak, Rille</creatorcontrib><creatorcontrib>Fong, Caroline</creatorcontrib><creatorcontrib>Starling, Naureen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pihlak, Rille</au><au>Fong, Caroline</au><au>Starling, Naureen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Therapies and Developing Precision Medicine in Gastric Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-06-19</date><risdate>2023</risdate><volume>15</volume><issue>12</issue><spage>3248</spage><pages>3248-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, various new targets and novel treatments have recently been investigated and have shown promise in improving survival outcomes. In this review, we will summarise previous and currently ongoing studies on predictive biomarkers, possible new targeted treatments, potential reasons for conflicting trial results and hope for the future of precision medicine in gastric cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37370858</pmid><doi>10.3390/cancers15123248</doi><orcidid>https://orcid.org/0000-0002-1496-6792</orcidid><orcidid>https://orcid.org/0000-0002-6055-334X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2023-06, Vol.15 (12), p.3248
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10296575
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central Free
subjects Biomarkers
Cancer
Cancer therapies
Chemotherapy
Drug therapy
ErbB-2 protein
FDA approval
Gastric cancer
Immunotherapy
Ipilimumab
Medical research
Medicine, Experimental
Patients
Population
Precision medicine
Response rates
Review
Stomach cancer
Survival
Tumors
title Targeted Therapies and Developing Precision Medicine in Gastric Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T01%3A05%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Therapies%20and%20Developing%20Precision%20Medicine%20in%20Gastric%20Cancer&rft.jtitle=Cancers&rft.au=Pihlak,%20Rille&rft.date=2023-06-19&rft.volume=15&rft.issue=12&rft.spage=3248&rft.pages=3248-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15123248&rft_dat=%3Cgale_pubme%3EA754975974%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c489t-6dc2af8c4065696d5f80601643e2566e1723adf4c1a48e3a3eb24f9e4cee93073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2829780699&rft_id=info:pmid/37370858&rft_galeid=A754975974&rfr_iscdi=true